Shows
Peer-SpectivesFDA Approvals, Pivotal Trial Data Change Approach to Breast Cancer ProgressionRecent approvals by the U.S. Food and Drug Administration (FDA) and findings from pivotal clinical trials have changed care for patients with breast cancer that has progressed after frontline hormone therapy. Ruth M. O’Regan, MD, chair of medicine and Charles H. Dewey Professor at the University of Rochester in New York, highlights which recent developments regarding second- and third-line treatments are most essential. She and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer Center in Los Angeles, discuss which newly approved drugs are making a difference in patients with actionable mutations, as...2024-02-1411 minPeer-SpectivesControversies, Difficult Questions Arise in NSCLC Amid New DataRecent data on the use of immunotherapy and targeted treatments in patients with advanced non-small cell lung cancer (NSCLC) have introduced a myriad of questions. These include controversial topics and difficult decisions, like when to incorporate CTLA-4 inhibition and what patients can expect from immuno-oncology monotherapy in the metastatic setting. Edward B. Garon, MD, MS, professor in the department of medicine in hematology/oncology and director of the thoracic oncology program at the Jonsson Comprehensive Cancer Center at the University of California Los Angeles, discusses key challenges in NSCLC care with Robert A. Figlin, MD, the Steven Spielberg Family...2024-02-1211 minPeer-SpectivesWhat FDA Approval of Belzutifan Means for Kidney Cancer CareBelzutifan was recently approved by the U.S. Food and Drug Administration (FDA) for use in previously treated adults with advanced renal cell carcinoma. How should this drug best be incorporated into practice? Eric Jonasch, MD, professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer Center in Los Angeles, discuss how the medication might be used in clinic. Dr. Jonasch also provides insight into the LITESPARK-005 study, which led to the FDA approval, as...2024-02-0510 minPeer-SpectivesDespite Lack of Head-to-Head Trials, Practice Patterns Shifting in Breast CancerCDK4/6 inhibitors “have really been a game changer” in metastatic breast cancer, according to Komal Jhaveri, MD, clinical director for early drug development and section head for endocrine therapy research at Memorial Sloan Kettering in New York City. However, optimal treatment strategies have been complicated by a lack of head-to-head trials. Dr. Jhaveri speaks with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer Center in Los Angeles, about how “practice patterns have slightly shifted” despite challenges in assessing efficacy across regimens and approaches. Dr. Jhaveri also discusses her work on the INAVO120 study, which fo...2024-02-0112 minPeer-SpectivesWhich FDA Approvals, Other Advances Changed ER-Positive Breast Cancer Care in 2023?From compelling data presented at the San Antonio Breast Cancer Symposium to the recent U.S. Food and Drug Administration approval of capivasertib, 2023 saw numerous key advances in breast cancer care. Aditya Bardia, MD, MPH, director of the breast cancer research program at Massachusetts General Hospital and associate professor at Harvard Medical School in Boston, and Robert A. Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars-Sinai Cancer Center in Los Angeles, discuss how several notable developments are already impacting practice. Dr. Bardia explains why genotyping is essential, provided it is available and affordable, and what recent...2023-12-1810 minPeer-Spectives“New Disruptor” in Prostate Cancer: PSMA PET and Other Treatment AdvancesFrom the use of prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) to advancements in targeted treatments, prostate cancer care is quickly evolving. Edwin M. Posadas, MD, director of the Experimental Therapeutics Program and director of the Center for Urologic Oncology Research Excellence at Cedars-Sinai in Los Angeles, speaks with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai, about how he is already implementing promising new data into practice. Although Dr. Posadas notes that although immunotherapy approaches in prostate cancer have been “a bit of a disappointment” so far, he sees “a lot of exciting resear...2023-12-1511 minPeer-SpectivesPractice-Changing Results in Prostate Cancer, as Enzalutamide Regimens Show Strong BenefitResults of the recent EMBARK study show that both enzalutamide plus leuprolide and enzalutamide monotherapy significantly improved metastasis-free survival compared with leuprolide alone in patients with prostate cancer who have high-risk biochemical recurrence. Lead author Stephen Freedland, MD, associate director for education and training and director of the Center for Integrated Research in Cancer and Lifestyle at Cedars-Sinai Cancer Center in Los Angeles, speaks with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai, about how these findings should be applied in practice. Although the data represent a significant advance, Dr. Freedland suggests even more...2023-12-1411 minPeer-SpectivesER-Positive Breast Cancer Advances and Other Eagerly Anticipated Data at SABCS 2023Studies involving high-risk, early-stage ER-positive breast cancer are among the most eagerly anticipated at this year’s San Antonio Breast Cancer Symposium (SABCS), to be held Dec. 5-9. Virginia Kaklamani, MD, professor of medicine in the division of hematology and medical oncology at the University of Texas Health Sciences Center San Antonio and leader of the breast cancer program at the Mays Cancer Center, discusses which data she thinks has the best chance of changing practice soon. She also speaks with Bob Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars-Sinai Cancer Center in Los Angeles, about ke...2023-11-2011 minPeer-SpectivesInside ODAC’s Vote on Sotorasib in Advanced and Metastatic NSCLC: Lessons LearnedLast month, a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) determined that progression-free survival (PFS) could not be reliably interpreted in a confirmatory clinical trial for sotorasib (Lumakras) used to treat KRAS G12C–mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Ravi A. Madan, MD, senior clinician at the National Cancer Institute’s Center for Cancer Research and chair of the ODAC, speaks with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer Center in Los Angeles, about broader implications from the 2-10 vote against the sotor...2023-11-1513 minPeer-SpectivesFirst-Line Osimertinib Plus Chemo in NSCLC: How to Weigh Toxicity vs. EfficacyHow should results of the FLAURA2 clinical trial be applied in practice? The study examined the use of osimertinib plus chemotherapy in the first-line treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared with osimertinib alone and found that progression-free survival was significantly improved with the combination treatment. Pasi A. Jänne, MD, PhD, director of three cancer centers at the Dana-Farber Cancer Institute in Boston, including the Lowe Center for Thoracic Oncology, shares his team’s findings with Bob Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars-Sinai Cancer Center in Los Angeles. They discuss toxic...2023-11-0709 minPeer-SpectivesWhat Recent “Outstanding Results” in MCL Mean for Practice“Therapies are improving dramatically” in mantle cell lymphoma (MCL), according to Michael Wang, MD, professor in the department of lymphoma/myeloma, division of cancer medicine at the University of Texas MD Anderson Cancer Center in Houston. Dr. Wang presented updates on major advances in MCL at the recent Society of Hematologic Oncology (SOHO) annual meeting. Here, he speaks with Bob Figlin, MD, the Steven Spielberg family chair in hematology-oncology at Cedars-Sinai Cancer Center in Los Angeles, about which promising regimens from recent studies are most appropriate for certain age groups. Dr. Wang...2023-10-2711 minPeer-SpectivesThe Quest to Cure CLL: “Remarkable” Results With New StrategyRecent advances have provided new options for when and how best to treat patients with chronic lymphocytic leukemia (CLL). Trials of combination strategies have shown promise in providing patients the potential for unmaintained remissions. Marco Ruella, MD, an assistant professor of medicine in hematology-oncology at the Perlman School of Medicine at the University of Pennsylvania and scientific director of the lymphoma program, speaks with Robert Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars-Sinai Cancer Center in Los Angeles, about the current state of CLL care and what changes are likely in the near future. Although satisfied i...2023-09-0616 minPeer-SpectivesWhich Data From the 2023 World Conference on Lung Cancer Are Most Likely to Change Practice?The World Conference on Lung Cancer (World Lung) will be held in Singapore, September 9–12. The current president of International Association for the Study of Lung Cancer (IASLC), Heather A. Wakelee, MD, division chief of medical oncology at the Stanford Cancer Institute in California, shares which presentations and findings she is most looking forward to at this year’s event. She speaks with Robert Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars-Sinai Cancer Center in Los Angeles, about steps being taken to ensure that key information from the conference is communicated quickly, clearly, and effectively to community onco...2023-08-1514 minPeer-Spectives“Really Impactful” New Guidelines for Stage IV NSCLC With Driver AlterationsUpdates to the American Society for Clinical Oncology’s (ASCO’s) living guidelines for therapy in patients with stage IV non-small cell lung cancer (NSCLC) with driver alterations were recently released. Dwight H. Owen, MD, MS, from The Ohio State University Comprehensive Cancer Center – James, examines the new recommendations that he and his team introduced with Bob Figlin, MD, the Steven Spielberg family chair in hematology-oncology at Cedars-Sinai Cancer Center in Los Angeles. They discuss how the living guidelines are updated and the rationale for what gets included, a process Dr. Figlin notes is “critical to the practicing oncologist.” Dr. Owen d...2023-08-0315 minPeer-SpectivesMore “Cage Rattling,” Less Talking: Susan Love’s Lessons for OncologistsIn early July, beloved surgeon and breast cancer advocate Susan Love, MD, MBA, died at age 75 years, after a recurrence of leukemia. Dr. Love’s legacy extends beyond the lives of her patients and into the approaches and attitudes of her fellow physicians. Stephanie Graff, MD, medical advisor to the Dr. Susan Love Foundation for Breast Cancer Research and director of breast oncology at the Legorreta Cancer Center at Brown University in Providence, Rhode Island, shares memories and insights about Dr. Love with Bob Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars-Sinai Cancer in Los Angeles. Th...2023-07-1813 minPeer-SpectivesWill HER3 Targeting Change Breast Cancer Care?HER2 inhibitors dramatically changed care for many breast cancers; however, less is known about HER3, which acts in concert with HER2. Does HER3 have the same potential to reshape treatment strategies? Erika Hamilton, MD, director of breast cancer and gynecologic cancer research at Sarah Cannon Research Institute in Nashville, talks with Bob Figlin, MD, the Steven Spielberg family chair in hematology-oncology at Cedars-Sinai Cancer Center in Los Angeles, about HER3, how it works, and how new antibody-drug conjugates (ADCs) that target HER3 are already showing activity in hard-to-treat disease. She also explains how sequencing ADC therapies may work and...2023-06-2712 minPeer-Spectives“Practice-Expanding” Data on Adjuvant Osimertinib in NSCLC: Steps to Take Now Although findings have suggested that adjuvant osimertinib is beneficial in early-stage non-smallcell lung cancer (NSCLC), some concerns have persisted. Balazs Halmos, MD, MS, associate director of clinical science, and director of both thoracic oncology and clinical cancer genomics at Montefiore Einstein Cancer Center in New York, says that “all these doubts have been shifted away,” given recent data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Halmos speaks with Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer in Los Angeles, about data from the ADAURA trial and other studies. Dr. Halmos says...2023-06-2713 minPeer-Spectives“Don't Just Throw Drugs Together”: How to Best Approach ESR1 Mutations in Breast CancerHow should community oncologists best approach ESR1 mutations in breast cancer, given the latest findings? Recent data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and elsewhere have shed light on issues related to ESR1 testing and treatment selection. Bob Figlin, MD, the Steven Spielberg Family Chair in hematology oncology at Cedars-Sinai Cancer in Los Angeles, speaks with Hope Rugo, MD, professor of medicine in the division of hematology and oncology, department of medicine, and director of breast oncology and clinical trials education at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center...2023-06-2013 minPeer-SpectivesmRNA Cancer Vaccines: When to Expect FDA Approval, and What’s Next?Recent results demonstrated that mRNA vaccination improved recurrence-free survival among patients with melanoma. This has led to questions about what’s next for this promising intervention. Bob Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars Sinai Cancer in Los Angeles, welcomes Jeffrey Weber, MD, PhD, deputy director, professor, and co-director of the melanoma research program at NYU Langone’s Perlmutter Cancer Center, todiscuss potential timing for FDA approval and additional cancers that may see benefit from a vaccine strategy.2023-05-1711 minPeer-Spectives“Major Wins” in Lung Cancer Treatment: How “Explosion of Data” Is Changing Practice Within the last few years, an “explosion of data” regarding adjuvant and neoadjuvant treatment for resectable lung cancer has contained “major wins” for patient care. Although exciting, the rapid advancement has led to questions about when chemotherapy and chemoimmunotherapy should be adopted or avoided. Bob Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars Sinai Cancer in Los Angeles, and Charu Aggarwal, MD, MPH, the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania’s Abramson Cancer Center in Philadelphia, discuss how to apply key recent findings. They also share “the special sauce” that...2023-05-0911 minPeer-Spectives“Great Therapies for All-Comers” in CLL: How Can Oncologists “Pick and Choose?”As treatment options increase for patients with CLL, so do questions about which interventions, if any, are right for which patients and when. Bob Figlin, MD, and Nicole Lamanna, MD, discuss key considerations, ranging from cardiac toxicity to why Dr. Lamanna “won't just treat for a symptom.”2023-04-1814 minPeer-SpectivesPragmatica-Lung Tests a Treatment and a New Approach to TrialsThe newly opened Pragmatica-Lung trial compares ramucirumab plus pembrolizumab versus usual care for treatment of stage IV or recurrent non-small cell lung cancer. The trial is designed to ease enrollment requirements and data collection needs, focusing on the key endpoint of overall survival. Listen as study lead Karen Reckamp, MD, professor and division director for Cedar Sinai Cancer and Medical Oncology, and Bob Figlin, MD, the Steven Spielberg Family Chair in hematology oncology at Cedar Sinai Cancer, talk about how the trial came about and why it could change how future studies are done across cancer types2023-03-1709 minPeer-SpectivesThe Best First Step in Metastatic NSCLC CareWith more than 10 known driver mutations in non-small cell lung cancer (NSCLC), testing is ever more critical, says Heather Wakelee, MD, division chief of medical oncology at Stanford University and president of the International Association for the Study of Lung Cancer. Listen as she and Peer-Spectives host Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology Oncology at Cedars-Sinai Cancer, talk about how she manages patients with metastatic disease or those who need adjuvant treatment, when she starts targeted therapy or immunotherapy, and more. “We can drastically change the course of disease for a patient by giving them th...2023-03-1009 minPeer-SpectivesNeo- and Adjuvant Treatments Are Changing Care in Early NSCLCTreatment options are expanding quickly in early non-small cell lung cancer. Listen as Heather Wakelee, MD, division chief of Medical Oncology at Stanford University and president of the International Association for the Study of Lung Cancer, describes how she’s using new agents and incorporating trial findings into practice. She and host Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology Oncology at Cedars-Sinai Cancer, explore the growing roles for neo- and adjuvant therapy and how to select patients for each therapeutic approach.2023-03-0611 minPeer-SpectivesNALIRIFOX Changes Care in Pancreatic Cancer: Here’s HowAfter a decade of limited gains in metastatic pancreatic cancer, Zev Wainberg, MD, professor of medicine and co-director of the GI oncology program at the University of California, Los Angeles, presented the results of the NAPOLI-3 trial at the ASCO Gastrointestinal Cancers Symposium last month. The data showed an improvement in overall survival and usher in a new standard for the hard-to-treat disease. Listen as Dr. Wainberg talks with Bob Figlin, MD,Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer, and host of OBR’s Peer-Spectives podcast, about those data and which patients should receive the regimen. They also ta...2023-02-1610 minPeer-SpectivesMatching Breast Cancer Patients to Therapies: Here’s How The landscape for breast cancer treatment is shifting quickly, with an ever-increasingemphasis on targeted and hormonal therapies. Listen as Virginia Kaklamani,MD, professor of medicine in the division of hematology oncology at UT Health San Antonio, and medical directorof the breast oncologyprogram at UT Health San Antonio, MD Anderson Cancer Center,talks with Bob Figlin, MD, Steven Spielberg Family Chair in Hematology-OncologyatCedars-Sinai Cancer,about key findings coming out of the 2022 San Antonio Breast Cancer Symposium. She shares how she’ll use elacestrant following updated results from the EMERALD trial, how to select patients for ovarian suppression, and the expanding role of...2022-12-1611 minPeer-SpectivesMyelofibrosis Remains Tough to Treat, But New Drugs Are Paving the WayListen as Gabriela Hobbs, MD, clinical director of the leukemia atMass General, talks with Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology Oncology at Cedars-Sinai Cancer in Los Angeles, about the latest progress in the treatment of myelofibrosisand how she both assesses new patients and plans their treatment. New agents, including JAK2 inhibitors,are not curative but can have substantial effects on patients and open up further treatment options. Dr. Hobbs also talks about new drug classes on the horizon and what to expect at the upcoming ASH meeting.2022-11-1113 minPeer-SpectivesKRAS Inhibition in NSCLC: When, How, and Why?Melissa Johnson, MD,a medical oncologist with Tennessee Oncology and Director of Lung Cancer Research at Sarah Cannon Research Institute in Nashville,joins host Robert Figlin, MD, Steven Spielberg Family Chair in HematologyOncologyat Cedars-Sinai Cancer, to talk about KRAS G12C inhibition in non-small cell lung cancer (NSCLC)treatment. She talks about how she uses sotorasib (Lumakras), which is U.S. Food and Drug Administration (FDA)approved for second-line treatment, why plasma-based genetic testing is so important, and how she explains to patients that even though she can’t start them off with this drug in the first-line, having it in...2022-11-1114 minPeer-SpectivesStrategies for Navigating a Hematology/Oncology FellowshipThe key steps to launching a successful and professionally fulfilling hematology/oncology fellowship is to “reflect, project, and adapt,” according to Gerald Hsu, MD, PhD, associate clinical professor of medicine and director of the Hematology/Oncology Fellowship Program at UCSF. Dr. Hsu spoke with Robert Figlin, MD, to discuss how new fellows can best navigate the opportunities they’re presented with. Dr. Hsu recommends reflecting on your areas of passion and interest, projecting what you’ll need 10 years down the road, and adapting your goals as your priorities and interests evolve.2022-11-0414 minPeer-SpectivesTaking Aim at MET and KRAS in NSCLCTejas Patil, MD, assistant professor of medical oncology at the University of Colorado Cancer Center, talks with Robert A. Figlin, MD, about new targeted therapies for non-small cell lung cancer (NSCLC), particularly tepotinib (Tepmetko) for MET exon 14 and sotorasib (Lumakras) for KRAS G12C. The MET exon 14 skip mutation has attracted renewed attention because tepotinib and capmatinib (Tabrecta), which both target this mutation, recently received FDA approvals. But MET can be disrupted in other ways, as well. Listen as Dr. Patil discusses the different types of MET alterations, how to identify MET activation in patients, and best practices for...2022-10-2912 minPeer-SpectivesMantle Cell Lymphoma: Optimizing Current Therapies Jonathan Cohen, MD, MS, Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine, , joins OBR Editor-in-Chief Robert Figlin, MD, to talk about mantle cell lymphoma. Dr. Cohen describes the key to making a correct diagnosis and what the best frontline treatment approaches are for different patient groups. He also talks about how BTK inhibitors and CAR T-cell therapy are shifting the treatment landscape and what he’s anticipating will be presented at upcoming conferences. “One of the things I know I've learned about mantle cell lymphoma is that if you wait six months, something new will...2022-10-2812 minPeer-SpectivesCOSMIC-313 trial and the Complex Treatment Landscape for Metastatic Renal Cell Cancer: How Do You Decide?Bob Figlin, MD, and Toni Choueiri, MD, the director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, discuss the early results from the COSMIC-313 trial, which Dr. Choueiri presented at ESMO 2022. The trial enrolled previously untreated patients with metastatic clear cell renal cell cancer who were classified as intermediate- to poor-risk. Standard of care doublet therapy, nivolumab (nivo) plus ipilimumab (ipi), was compared with triplet therapy, consisting of nivo-ipi plus cabozantinib. Triplet therapy improved progression-free survival compared with doublet therapy, specifically in the intermediate-risk group. Dr. Choueiri also discussed the complicated landscape in RCC and how...2022-10-1912 minPeer-SpectivesFinding Joy in Work: ASCO’s Career Development Resources Help Trainees Choose Their Path Bob Figlin, MD, and Jamie Von Roenn, MD, discuss strategies for learning about the oncology specialty earlier in the training pipeline, particularly for under-represented groups. They also look at opportunities for oncology fellows to build skills in different career areas. 2022-10-0414 minPeer-SpectivesConsidering an Oncology Fellowship? Listen to This FirstGerald Hsu, MD, PhD, UCSF’s hematology/oncology fellowship program director, joins Robert Figlin, MD, to talk about what fellowship programs are looking for in applicants, how trainees can find programs that are a good fit, and why preparing for an interview improves the odds you land at the right spot for you.2022-09-0617 minPeer-SpectivesKidney Cancer at a Crossroads: What New Trial Results Could Mean for Patients Michael B. Atkins, MD, and Robert Figlin, MD, discuss results from the EVEREST clinical trial as well as new data on TKIs, immunotherapy, and HIF-2 inhibitors. They also discuss adjuvant therapy and how depth of response differs between immunotherapy and TKIs, and look ahead to what the future holds.2022-08-1913 minPeer-SpectivesHow to Choose CLL Treatments in the Frontline Setting Danielle Brander, MD, talks with Robert Figlin, MD, about selecting frontline treatments for CLL and how she talks with patients about their treatment options. “What I think is unique about the last few years is we’ve seen multiple randomized trials in the frontline setting that have shown not only superior progression-free survival … but several of those randomized studies also showing improvement in overall survival versus chemoimmunotherapy,” Dr. Brander said. “I think it’s really important for us to be considering these novel treatment options.”2022-07-0811 minPeer-SpectivesRethinking HER2-Targeted Therapy After DESTINY-04 William Gradishar, MD, talks with Robert Figlin, MD, about breast cancer research highlights from the 2022 American Society of Clinical Oncology Annual Meeting, including results from DESTINY-Breast04 and new data on CDK4/6 inhibitors from the PALOMA-2 and MAINTAIN trials.2022-07-0711 minPeer-SpectivesMost Patients with BRAF-mutant Metastatic Melanoma Benefit from First-line ImmunotherapyMichael B. Atkins, MD, talks with Robert A. Figlin, MD, about the importance of sequencing therapies for patients with BRAF-positive metastatic melanoma. Data from the DREAMSeq trial, which Dr Atkins updated at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, show a significant survival advantage at two years for patients who receive ipilimumab plus nivolumab prior to receiving a BRAF/MEK inhibitor. But not all patients fit that paradigm. Listen as Dr Atkins shares which patients he starts on immunotherapy and when he thinks is the best time for crossover to a targeted agent.2022-06-1612 minPeer-SpectivesAdjuvant and Neoadjuvant Therapy for NSCLC: Who to Treat and With What AgentListen in as Roy Herbst, MD, PhD, shares with Robert Figlin, MD, how he approaches treatment for patients with early-stage non-small cell lung cancer after the ADAURA and CHECKMATE-816 trials. They discuss different factors that influence use of adjuvant and neoadjuvant treatments, including stage, EGFR mutation status, and PD-L1 status.2022-05-0512 minPeer-SpectivesThe Complex Decisions in CLL Treatment Today: Clarifying the ChoicesLori Leslie, MD, and Robert Figlin, MD, discuss the latest drugs and clinical trial data on CLL treatment. Dr. Leslie shares her strategy for sequencing agents, including various BTK inhibitors and venetoclax, and how she decides on treatment in patients whose disease progresses or are refractory.2022-04-1313 minPeer-SpectivesDREAMseq Trial: What It Means for Metastatic Melanoma TreatmentSapna Patel, MD, Associate Professor at MD Anderson Cancer Center, and Robert Figlin, MD, Deputy Director at Cedars-Sinai Cancer, discuss the clinical implications of the DREAMseq trial, showing patients with BRAF-mutant metastatic melanoma live longer if they receive first-line ipilimumab plus nivolumab.2022-03-2911 minPeer-SpectivesThe Latest Thinking Regarding Adjuvant Pembrolizumab in Renal Cell Carcinoma Post-ASCO GU ‘22Rana McKay, MD, Allan Pantuck, MD, and Robert Figlin, MD, discuss the recent update to the Keynote-564 study investigating adjuvant pembrolizumab in RCC and the impact on high-, medium-, and low-risk patients. They also talk about the Disease-Free Survival (DFS) endpoint, discussing the study with patients, and the recent NCCN guidelines update.2022-03-1121 minPeer-SpectivesPost ASCO GU ’22 – Muscle-Invasive Bladder Cancer, EV-103, Enfortumab Vedotin, and the Clinical Progress Being Made Managing MIBC PatientsDaniel Petrylak, MD, Professor of Medicine at the Yale Cancer Center, and Robert Figlin, MD, of Cedars-Sinai Cancer discuss recent developments at ASCO GU in muscle-invasive bladder cancer and in particular the EV-103 clinical study while also discussing the future of MIBC treatment.2022-03-0709 minPeer-SpectivesThe HIMALAYA Study Presented at ASCO GI ’22: An Update on the State of Liver Cancer Treatment TodayGhassan Abou-Alfa, MD and Robert Figlin, MD, discuss the presentation of the HIMLAYA clinical study at ASCO GI ’22 and how this regimen may fit in the liver cancer treatment landscape2022-01-2610 minPeer-SpectivesFrederick Locke, MD of Moffit Cancer Center and Robert Figlin, MD of Cedars-Sinai discuss ZUMA-7, the role of CAR-T in the management of relapsed/refractory B-cell lymphoma, and recent clinical data presented at ASH ‘21Frederick Locke, MD and Robert Figlin, MD discuss ZUMA-7 and when to start thinking about integrating CAR-T into B-cell lymphoma treatment algorithms, the role of BMT in these patients, and how recent data presented at ASH ’21 shows that CAR-T cell therapies can work well in relapsed/refractory B-cell lymphoma.2021-12-2211 minPeer-SpectivesFrom SABCS ’21: Neoadjuvant Immunotherapy and the Use of the 21-Gene Signature TestLajos Pusztai, MD, and Robert Figlin, MD, discuss the practicality of neoadjuvant I-O as demonstrated in KEYNOTE-522 and the application of the Oncotype DX 21-gene signature test in the RxPONDER study, both presented at the 2021 San Antonio Breast Cancer Symposium.2021-12-1411 minPeer-SpectivesTargeted Therapy and Venclexta Combinations for AML and a Look Ahead to ASH ’21Naval Daver, MD, and Robert Figlin, MD, discuss FLT3, TP53, and venetoclax combinations in the management of AML patients and what to look forward to at ASH 2021. 2021-12-0211 minPeer-SpectivesAfter CodeBreaK100: Targeting KRAS in Non-Small Cell Lung CancerKathryn Arbour, MD, joins host Robert Figlin, MD, to discuss the importance of the KRAS-targeted drug, sotorasib, in the treatment of non-small cell lung cancer. Kathryn Arbour, MD, joins host Robert Figlin, MD, to discuss the role next-generation sequencing plays in lung cancer care, the responses seen with the KRAS-targeted drug, sotorasib, in CodeBreaK100, and what optimal use of the drug will look like down the road.2021-11-2011 minPeer-SpectivesESMO ’21: The ARCHES Study and Progress in Metastatic (and Non-Metastatic) Hormone-Sensitive Prostate CancerAndrew Armstrong, MD and Robert Figlin, MD discuss the ARCHES study investigating the role of enzalutamide in metastatic hormone-sensitive prostate cancer, followed by a discussion of the latest treatment trends in non-metastatic hormone-sensitive prostate cancer.2021-09-2209 minPeer-SpectivesRecent Clinical Progress in Ovarian CancerRobert Coleman, MD and Robert Figlin, MD, discuss the evolving role of bevacizumab in ovarian cancer, recently presented clinical studies such as BOOST and EFFORT, and the challenge of treating the PARP-refractory setting in advanced ovarian cancer.2021-07-1611 minPeer-SpectivesPost-EHA Latest Treatment Trends in the Management of Chronic Lymphocytic Leukemia (CLL)2021-07-1412 minPeer-SpectivesNon-Small Cell Lung Cancer Clinical Highlights From ASCO 2021Jeffrey Crawford, MD, and Robert Figlin, MD, discuss highlights from ASCO ’21 including immunotherapy, adjuvant and neoadjuvant therapy ie IMpower010 and Checkmate-816, and finish up with a discussion regarding molecular tests, MYLUNG, and NGS as it applies to NSCLC.2021-06-3011 minPeer-SpectivesColorectal Cancer Clinical Highlights From ASCO 2021Andrew Hendifar, MD, and Robert Figlin, MD, discuss highlights from the 2021 ASCO annual meeting, including immunotherapy in MSI-H/dMMR metastatic CRC patients, looking for DEEPER responses in RAS-wild type tumors, the need for testing for HER2+ CRC patients, and liquid biopsy and the CHRONOS trial.2021-06-1611 minPeer-SpectivesBreast Cancer Clinical Highlights from ASCO 2021Erika Hamilton, MD, of the Sarah Cannon Research Institute, and Robert Figlin, MD, of Cedars-Sinai Medical Center, discuss breast cancer research from the 2021 annual meeting of the American Society of Clinical Oncology, including adjuvant and neo-adjuvant breast cancer, metastatic disease, the role of CDK 4/6 inhibitors and PARP inhibitors, the potential of SERDs, and a negative study.2021-06-1510 minPeer-SpectivesNon Small Cell Lung Cancer (NSCLC) – Robert Figlin, MD, and Melissa Johnson, MD, discuss the different driver mutations in non small cell lung cancer (NSCLC)Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Program Director, Lung Cancer Research, Sarah Cannon Research Institute, discuss the different driver mutations in Non Small Cell Lung Cancer (NSCLC) and how to use them to guide treatment2021-05-2014 minPeer-SpectivesSmall Cell Lung Cancer (SCLC) – Robert Figlin, MD, and Melissa Johnson, MD, discuss clinical progress in small cell lung cancer (SCLC) Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Program Director, Lung Cancer Research, Sarah Cannon Research Institute, discuss clinical progress in Small Cell Lung Cancer (SCLC) 2021-03-3110 minPeer-SpectivesBladder Cancer – Robert Figlin, MD, and Arjun Balar, MD, discuss clinical progress in bladder cancer Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Arjun Balar, MD, Director, Genitourinary Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discuss clinical progress in bladder cancer 2021-02-2811 minPeer-SpectivesProstate Cancer – Robert Figlin, MD, and Neeraj Agarwal, MD, discuss clinical progress in prostate cancerRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Neeraj Agarwal, MD, Professor of Medicine, Huntsman Cancer Institute, Presidential Endowed Chair of Cancer Research , Co-Leader, HCI Experimental Therapeutics Program, Director, Center of Investigational Therapeutics, Director, Genitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, discuss clinical progress in prostate cancer2021-02-2212 minPeer-SpectivesRenal Cell Carcinoma (RCC) – Robert Figlin, MD and Toni Choueiri, MD, discuss clinical progress in renal cell carcinoma (RCC)Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Toni Choueiri, MD, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, discuss clinical progress in renal cell carcinoma (RCC)2021-02-2213 minPeer-SpectivesAcute myeloid leukemia (AML) and Acute lymphocytic leukemia (ALL) – David Sallman, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2020Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and David Sallman, MD, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center discuss CAR T as it pertains to clinical advances in leukemia2020-12-2212 minPeer-SpectivesRenal Cell Carcinoma (RCC) – Bradley McGregor, MD, and Robert Figlin, MD, discuss clinical highlights from ESMO 2020Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley McGregor, MD, Clinical Director, Lank Center for Genitourinary Oncology, Professor of Medicine, Harvard Medical School, discuss Checkmate 9ER and other I-O studies as they pertain to the management of RCC patients2020-10-2610 minPeer-SpectivesNon Small Cell Lung Cancer – Victoria Villaflor, MD, and Robert Figlin, MD, discuss unresectable stage III NSCLCRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Victoria Villaflor, MD, Clinical Professor, Director Head and Neck Oncology at City of Hope, discuss unresectable stage III Non Small Cell Lung Cancer (www.azioinpractice.com)2020-10-2108 minPeer-SpectivesGastric/GE Junction Cancer – Geoffrey Ku, MD, and Robert Figlin, MD, discuss recent clinical developments in gastric and esophageal cancerRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Geoffrey Ku, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discuss recent clinical developments in gastric and esophageal cancer2020-10-1613 minPeer-SpectivesBreast Cancer – Sara Hurvitz, MD, and Robert Figlin, MD, discuss recent clinical developments in early stage and late stage breast cancerRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Sara Hurvitz, MD, Associate Professor of Medicine, Geffen School of Medicine, UCLA, Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit, discuss breast cancer patient types, challenges, and treatment advances.2020-07-1715 minPeer-SpectivesAdjuvant Lung Cancer – Roy Herbst, MD, and Robert Figlin, MD, discuss the recent ASCO20 plenary presentation of the ADAURA study investigating the use of Tagrisso (osimertinib) in stage I-III EGFR+ NSCLC patientsRoy Herbst, MD, and Robert Figlin, MD, discuss the implications of the ADAURA study investigating the use of Tagrisso (osimertinib) in stage I-III EGFR+ NSCLC patients2020-06-2510 minPeer-SpectivesBreast Cancer – Nancy Lin, MD, and Robert Figlin, MD, discuss novel agents and recent clinical developments in breast cancer from ASCO20Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Nancy Lin, MD, Associate Professor of Medicine, Harvard Medical School Associate Chief, Division of Breast Oncology Dana-Farber Cancer Institute, discuss novel agents and recent clinical developments in breast cancer2020-06-1209 minPeer-SpectivesNon Small Cell Lung Cancer (NSCLC) – Edward Garon, MD, and Robert Figlin, MD, discuss promising agents in development for the management of NSCLC from ASCO20Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Edward Garon, MD, Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, Associate Professor of Medicine, David Geffen School of Medicine, UCLA, discuss promising agents in development for the management of NSCLC from ASCO202020-06-1111 minPeer-SpectivesColon and Rectal Cancer – David Ilson, MD, and Robert Figlin, MD, discuss recent clinical advances in colon and rectal cancer from ASCO20 VirtualRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and David Ilson, MD, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, discuss the progress in colon and rectal cancer presented at ASCO202020-06-0812 minPeer-SpectivesWaldenstrom macroglobulinemia – Constantine Tam, MD, and Robert Figlin, MD, discuss recent clinical advances in the treatment of Waldenstrom macroglobulinemia from ASCO20Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Constantine Tam, MD, Haematologist and Disease Group Lead, Low Grade Lymphoma and Chronic Lymphocytic Leukemia, Peter MacCallum Cancer Centre, discuss the progress in Waldenstrom macroglobulinemia from ASCO202020-06-0812 minPeer-SpectivesColorectal Cancer – Jeffrey Meyerhardt, MD, and Robert Figlin, MD, discuss recent clinical advances in CRC from ASCO20 VirtualRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Jeffrey A. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, discuss the progress in CRC presented at ASCO202020-06-0610 minPeer-SpectivesOvarian Cancer – BJ Rimel, MD, and Robert Figlin, MD, discuss recent studies and FDA approvals in ovarian cancerRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and BJ Rimel, MD, Assistant Professor, Obstetrics and Gynecology, Cedars-Sinai Medical Center, discuss recent clinical studies in ovarian cancer and how recent developments are impacting the way ovarian cancer patients are treated.2020-05-0711 minPeer-SpectivesRenal Cell Carcinoma (RCC) – Tian Zhang, MD, and Robert Figlin, MD, discuss recent clinical advances in RCC from ASCO GURobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Tian Zhang, MD, Assistant Professor of Medicine, Duke University School of Medicine, discuss the progress in RCC presented at ASCO GU '202020-03-2013 minPeer-SpectivesProstate Cancer – Daniel Petrylak, MD, and Robert Figlin, MD, discuss recent clinical advances in prostate cancer from ASCO GURobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Daniel Petrylak, MD, Professor of Medicine, Medical Oncology and Urology, Co-Leader, Cancer Signaling Networks, Yale Cancer Center, discuss the progress in prostate cancer presented at ASCO GU '202020-03-0208 minPeer-SpectivesColorectal Cancer – Zev Wainberg MD, and Robert Figlin, MD, discuss recent clinical advances in colorectal cancer from ASCO GIRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Zev Wainberg, MD, Assistant Professor of Medicine at UCLA and Co-Director of the UCLA GI Oncology Program, discuss the progress in colorectal cancer presented at ASCO GI '202020-02-1207 minPeer-SpectivesMantle Cell Lymphoma (MCL) – Michael Wang MD, and Robert Figlin, MD, discuss recent clinical advances in mantle cell lymphomaRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Michael Yang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson, discuss recent clinical advances in mantle cell lymphoma2020-02-0308 minPeer-SpectivesChronic Lymphocytic Leukemia (CLL) – Lori Leslie MD, and Robert Figlin, MD, discuss clinical highlights in the treatment of CLLRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Lori Leslie, MD, Medical Oncologist, Regional Cancer Care Associates, discuss clinical highlights in the treatment of CLL2020-01-1012 minPeer-SpectivesAcute Myeloid Leukemia (AML) – Courtney DiNardo MD, and Robert Figlin, MD, discuss the latest clinical developments in AMLRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discuss the latest clinical developments in AML2020-01-1014 minPeer-SpectivesCAR-T and Lymphoma – Michael Jain, MD, and Robert Figlin, MD, discuss the role of CAR-T in the treatment of lymphomaRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, discuss the role of CAR-T and the treatment of lymphoma and off-the-shelf CAR-T2019-12-2116 minPeer-SpectivesLung Cancer – Geoffrey Oxnard, MD, and Robert Figlin, MD, discuss integrating liquid biopsies into lung cancer careRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Geoffry R. Oxnard, MD, Associate Professor of Medicine, Associate Professor of Medicine, Dana Farber Cancer Instituate, Harvard Medical School, discuss integrating liquid biopsies into lung cancer care2019-11-2611 minPeer-SpectivesColorectal Cancer – Marwan Fakih, MD, and Robert Figlin, MD, provide post ESMO ’19 clinical updateRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Marwan Fakih, MD, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, discuss colorectal cancer clinical updates from ESMO 192019-10-2814 minPeer-SpectivesOvarian Cancer – Bradley Monk, MD, and Robert Figlin, MD, provide post ESMO ’19 clinical updateRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley Monk, MD, FACOG, FACS, Professor and Director of the Division of Gynecologic Oncology at Creighton University School of Medicine, discuss ovarian cancer clinical updates from ESMO 192019-10-1014 minPeer-SpectivesColorectal Cancer (CRC) – Scott Kopetz, MD, and Robert Figlin, MD, provide post World GI ’19 clinical updateRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Scott Kopetz, MD, PhD, FACP, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson, provide CRC clinical update post World GI '19.2019-07-3012 minPeer-SpectivesHepatocellular carcinoma (HCC) – Daneng Li, MD and Robert Figlin, MD, discuss clinical highlights from ASCO 2019Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, discuss HCC highlights from ASCO 2019.2019-07-0214 minPeer-SpectivesPancreatic Cancer – Vincent Chung, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO 2019Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Vincent Chung, MD, Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, discuss pancreatic cancer highlights from ASCO 2019.2019-06-2114 minPeer-SpectivesBreast Cancer – Neelima Denduluri, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO 2019Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Neelima Denduluri, MD, Medical Oncologist, Virgina Cancer Specialists, discuss breast cancer highlights from ASCO 2019.2019-06-2110 minPeer-SpectivesLung Cancer – Edward Garon, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO 2019Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Edward Garon, MD, Associate Professor of Medicine, Geffen School of Medicine at UCLA, discuss lung cancer highlights from ASCO 2019.2019-06-2114 minPeer-SpectivesGastric/GE Junction Cancer – Howard Hochster, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO 2019Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Howard Hochster, MD, Professor of Medicine Associate Director for Clinical Research and Director, GI Oncology, Rutgers Cancer Institute, discuss gastric/GE junction cancer clinical highlights from ASCO 2019.2019-06-2115 minPeer-SpectivesUrothelial Cancer – Bradley McGregor, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO 2019Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley McGregor, MD, Clinical Director, Lank Center for Genitourinary Oncology, Professor of Medicine, Harvard Medical School, discuss urothelial cancer clinical highlights from ASCO 2019.2019-06-2113 minPeer-SpectivesKeytruda RCC Approval/I-O – Toni Choueiri, MD, and Robert Figlin, MD, discuss the recent Keytruda approval in renal cell carcinoma (RCC)Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Toni Choueiri, MD, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, discuss Keytruda's approval in renal cell carcinoma (RCC).2019-05-1613 minPeer-SpectivesColorectal Cancer (CRC) – Axel Grothey, MD, and Robert Figlin, MD, provide clinical update in CRCRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Axel Grothey, MD, Director of GI Research, West Cancer Center, University of Tennessee, discuss new data from the BEACON study and the role of I-O and HIPEC in colorectal cancer2019-03-0514 minPeer-SpectivesRenal Cell Carcinoma (RCC) – Rana McKay, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO GU 2019Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Rana McKay, Assistant Professor of Medicine, University of California San Diego, discuss renal cell carcinoma (RCC) clinical highlights from ASCO GU 20192019-03-0514 minPeer-SpectivesHepatocellular Carcinoma (HCC) – Richard Finn, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO GI 2019Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Richard Finn, MD, Professor of Medicine at the Geffen School of Medicine, UCLA, discuss hepatocellular carcinoma (HCC) clinical highlights from ASCO GI 20192019-02-1315 minPeer-SpectivesBiliary Tract and GE Junction Cancers – Tanios Bekaii-Saab, MD, FACP, and Robert Figlin, MD, discuss clinical highlights from ASCO GI 2019Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Tanios Bekaii-Saab, MD, Professor, Mayo Clinic College of Medicine and Science, discuss biliary tract and GE junction cancer clinical highlights from ASCO GI 20192019-02-0813 minPeer-SpectivesCAR-T Cell Therapy – Frederick Locke, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2018Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Frederick Locke, MD, Program Co-Leader, Immunology, Moffitt Cancer Center discuss CAR-T clinical highlights from ASH 20182018-12-1909 minPeer-SpectivesMultiple Myeloma – Sagar Lonial, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2018Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Sagar Lonial, MD, Professor and Chair, Hematology & Medical Oncology, Chief Medical Officer, Winship Cancer Institute of Emory University, discuss ALCYONE, GRIFFIN, and maintenance therapy (TOURMALINE-MM3), and other multiple myeloma clinical studies presented at the American Society of Hematology 2018 meeting2018-12-1207 minPeer-SpectivesBreast Cancer – Debu Tripathy, MD, and Robert Figlin, MD, discuss clinical highlights from ESMO 2018Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Debu Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson, discuss IMpassion130, SOLAR-1 and other breast cancer clinical studies presented at the meeting2018-11-0211 minPeer-SpectivesHead & Neck Cancer – Barbara Burtness, MD, and Robert Figlin, MD, discuss clinical highlights from ESMO 2018Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Barbara Burtness, MD, Professor of Medicine (Medical Oncology) at the Yale University School of Medicine, discuss Keynote-048 and other H&N clinical studies presented at the meeting2018-10-2913 minPeer-SpectivesOvarian Cancer – Bradley Monk, MD, and Robert Figlin, MD, discuss clinical highlights from ESMO 2018Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley Monk, MD, FACOG, FACS, Professor and Director of the Division of Gynecologic Oncology at Creighton University School of Medicine, discuss BRCA1+ ovarian patients, PARP inhibitors and the results of the SOLO-1 clinical trial2018-10-2408 minPeer-SpectivesLung Cancer – Melissa Johnson, MD, and Robert Figlin, MD, discuss clinical highlights from the 19th World Lung ConferenceRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute about targeted therapy, prevention, I-O in NSCLC, and I-O in SCLC.2018-10-0513 minPeer-SpectivesLung Cancer – Paul Bunn, MD, and Robert Figlin, MD, discuss clinical highlights from the 19th World Lung ConferenceRobert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Paul Bunn, MD, Distinguished Professor, Division of Medical Oncology, University of Colorado about prevention, I-O in NSCLC, and I-O in SCLC.2018-10-0308 min